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ABSTRACT
The prevalence and persistence of antibodies against cytomegalovirus (CMV), herpes simplex virus
types 1 (HSV1) and 2 (HSV2), Helicobacter pylori and Chlamydia pneumoniae were determined in Alaskan
Eskimos. The study included 610 individuals (mean age 43 ± 15 years; 45% males) participating in the
Genetics of Coronary Artery Disease in Alaska Natives (GOCADAN) study. Archived serum samples
and those collected during the GOCADAN study were analysed for antibodies against the above
pathogens by ELISA. The current prevalence of antibody seropositivity was 94% to CMV, 90% to HSV1,
38% to HSV2, 80% to H. pylori, and 42% to C. pneumoniae. The persistence of antibodies (in both
archived and current samples) against CMV, HSV1 and H. pylori was high (83%, 84% and 67%,
respectively) compared with those against HSV2 (26%) and C. pneumoniae (29%). Moreover, the
seroconversion rates to these organisms were low. Most individuals acquired CMV, HSV1 and H. pylori
antibodies by the age of 24 years (94%, 90% and 72%, respectively), and >50% carried HSV2 and
C. pneumoniae antibodies by the age of 45 years. There were gender differences in antibody
seropositivity rates. Over 70% of individuals had antibodies to at least three of the ﬁve pathogens
tested. The study demonstrated the high prevalence and lifelong persistence of multiple antibodies,
suggesting chronic infections among Alaskan Eskimos.
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INTRODUCTION
It is commonly believed that the rate of cardio-
vascular disease (CVD) is low among Eskimos
[1,2]. However, recent studies have observed
increasing CVD in this population, with marked
regional differences in mortality and prevalence
among Alaskan Eskimos [3,4]. For example, the
mortality rate for ischaemic heart disease in the
Norton Sound region is two-fold higher than in
neighbouring areas. Although the change from
the traditional lifestyle is an important contribut-
ory factor, infections caused by herpes viruses,
Helicobacter pylori and Chlamydia pneumoniae have
been suggested as additional important athero-
sclerotic risk-factors [5–15]. However, to our
knowledge, there are no published reports that
refer speciﬁcally to the prevalence and persistence
of these viral and bacterial infections in the
Alaskan Eskimo population.
The present study was undertaken to deﬁne the
prevalence and persistence of antibodies against
cytomegalovirus (CMV), herpes simplex virus
types 1 (HSV1) and 2 (HSV2), H. pylori and
C. pneumoniae in Eskimos participating in the
Genetics of Coronary Artery Disease in Alaska
Natives (GOCADAN) study. GOCADAN is an
ongoing study of the relative contribution of
genetic and environmental factors to CVD, and
includes 1214 Eskimos belonging to 40 families in
nine villages in theNorton Sound region of Alaska.
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The ﬁndings regarding herpes virus, H. pylori and
C. pneumoniae infections may provide important
background information for studying diseases,
including CVD, among Alaskan Eskimos.
PATIENTS AND METHODS
Study subjects
The 610 subjects were participants in the GOCADAN study,
which began in 2000 under the auspices of a Medstar Research
Institute IRB-approved protocol. An attempt was made to
recruit all families in the villages chosen for the study. Written
informed consent was obtained for all study participants.
Consenting household members aged ‡18 years were inter-
viewed to determine the name, gender, date and place of birth
of household members, relationships among household mem-
bers, and the parents and grandparents of each participant. A
physical examination was performed, a clinical survey was
completed, and a blood sample was collected.
Measurement of antibodies
Each individual (including those aged 18–24 years) provided
two serum samples for paired serological testing. The ﬁrst
(archived) samples were collected 15–20 years previously (for
other purposes before the GOCADAN study) and were stored
at the CDC, Alaska, USA; aliquots were thawed only when
speciﬁc tests were performed. The current samples were
obtained during the GOCADAN study (2000–2003) and were
stored at the Medstar Research Institute, Washington, DC,
USA. All sera were frozen at )80C, and the archived-current
pairs were tested as paired samples simultaneously.
Commercially available ELISA kits were used to determine
IgGs against CMV, H. pylori (Wampole, Cranbury, NJ, USA)
and HSV1 and HSV2 (Focus, Cypress, CA, USA). Cut-off
values for seropositivity, or for an increase or decrease in
antibody levels, were determined according to the manufac-
turers’ instructions. Brieﬂy, seropositivity for CMV, H. pylori,
HSV1 or HSV2 was deﬁned as an index value of ‡1.1. The
index values of the pairs were compared by calculating:
index value (current) index value (archived)=
index value (archived) 100%
¼ % rise in index value
Values ‡30% were considered as an elevated antibody level.
IgG, IgA and IgM serum antibodies to C. pneumoniae were
measured by the microimmunoﬂuorescence (MIF) method,
using elementary bodies (EBs) of Finnish strain Kajaani 6 as
the antigen, at the Laboratory for Chlamydia and Respiratory
Bacterial Infections, National Public Health Institute, Finland.
Two-fold serum dilutions were used, with the highest serum
dilution demonstrating good even ﬂuorescence of the EBs
being recorded as the titre. A C. pneumoniae IgG titre ‡1 : 32
was considered to be seropositive [16].
Statistical analysis
Data distributed normally are presented as the mean and
standard deviation (SD), while data distributed non-normally
are presented as the median and interquartile range (IQR).
Comparisons between endpoints were made using t-test
parametric distributions and the Mann–Whitney U-test for
non-parametric distributions. Categorical data were analysed
by the chi-square test, or Fisher’s exact test for small samples.
All tests were two-sided, with p < 0.05 considered signiﬁcant.
The co-variables considered were age, gender, smoking,
village and seropositivity to infectious agents. SAS software
(SAS Institute, Cary, NC, USA) was used for all analyses.
RESULTS
Antibody prevalence
Of the 610 individuals studied, 45% were male,
the mean age was 42.8 ± 15.3 years (range 18–
92 years), 82% were smokers, and the mean body
mass index was 27.8 ± 5.6 kg ⁄m2. The current
seropositivity rates to CMV, HSV1, HSV2, H. py-
lori and C. pneumoniae were 94%, 90%, 38%, 80%
and 42%, respectively (Table 1). With the excep-
tion of C. pneumoniae, the current seropositivity
rates were higher than those in the archived
samples (Table 1; all p < 0.01).
Persistence of antibodies
Persistent seropositivity rates were high for CMV
(83%), HSV1 (84%) and H. pylori (67%), com-
pared with HSV2 (26%) and C. pneumoniae (29%)
(Table 2). Moreover, the antibody seroconversion
rates for these infections were low. Interestingly,
75% of individuals with persistent CMV antibod-
ies, and 83% and 46%, respectively, of those with
H. pylori and C. pneumoniae antibodies, had per-
sistent stable elevated antibody levels. In contrast,
persistent stable antibody levels were less preval-
ent in individuals with HSV1 (25%) or HSV2
(13%) infection.
Table 1. Prevalence of serological markers for infection in
Eskimos
Seropositivitya Archived samplesb Current samplesc
Anti-CMV IgG, % (mean ± SD) 84.4 (2.4 ± 1.2) 93.5 (3.0 ± 1.1)
Anti-HSV1 IgG, % (mean ± SD) 85.3 (5.6 ± 2.7) 90.4 (5.5 ± 2.4)
Anti-HSV2 IgG, % (mean ± SD) 27.8 (1.3 ± 2.3) 38.5 (2.0 ± 3.2)
Anti-Helicobacter pylori IgG,
% (mean ± SD)
75.3 (1.6 ± 0.7) 80.0 (1.7 ± 0.6)
Anti-Chlamydia pneumoniae IgG,
% (mean ± SD)d
43.1 (41.5 ± 67.9) 42.4 (51.1 ± 138.4)
CMV, cytomegalovirus; HSV, herpes simplex virus.
aData are expressed as a percentage antibody seropositivity and mean level.
bArchived blood samples were obtained 15–20 years before the GOCADAN Study.
cCurrent blood samples were obtained during the GOCADAN Study.
dAnti-C. pneumoniae IgG titres >1:32 were considered seropositive.
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Multiple infections
Fig. 1 shows the relative frequencies of individuals
exposed to different numbers of infectious agents,
as reﬂected by the presence of speciﬁc IgG anti-
bodies in the archived and current serum samples.
Over 70% of individuals had been exposed to
three or more of the ﬁve pathogens tested, indica-
ting that multiple chronic infections (pathogen
burden) in Alaskan Eskimos are common.
Current prevalence of antibodies by age,
gender and village
Based on the current prevalence, it appeared that
most individuals had acquired CMV, HSV1 and
H. pylori antibodies by the age of 24 years (94%,
90% and 72%, respectively), and >50% had HSV2
and C. pneumoniae IgG antibodies by the age of
45 years (Table 3). Females had signiﬁcantly
higher positivity rates for CMV and HSV2 anti-
bodies than males, but males had higher positiv-
ity rates for H. pylori and C. pneumoniae
antibodies (Table 4). There were no signiﬁcant
differences in the prevalence of antibodies among
individuals from different villages (data not
shown).
DISCUSSION
The present study demonstrates that CMV, HSV1
and H. pylori antibodies are highly prevalent
(>80%) among Alaskan Eskimos. Antibodies
were acquired mainly early in life, and had a
lifelong persistence with stable elevated levels.
The prevalence rates of antibodies to HSV2 and
C. pneumoniae were relatively lower than those to
CMV, HSV1 and H. pylori. The seropositivity
rates increased with age, and >50% of individuals
became seropositive during the fourth and ﬁfth
decades of life. Interestingly, there were gender
differences, in that higher seropositivity rates for
CMV and HSV2 were found in women, but men
had higher seropositivity rates for H. pylori and
C. pneumoniae. Furthermore, >70% of individuals
had been exposed to at least three of the ﬁve
pathogens tested.
Although infection surveillance data are lim-
ited for Alaskan Eskimos, studies in the Canadian
Arctic have reported similarly high (50–95%)
seroprevalence rates for H. pylori infection, and
seropositive subjects were more likely to be men
[17,18]. Early data from the Alaskan Native
population showed that there was a high
(75%) seroprevalence for H. pylori [19], and
Table 2. Seropositivity features of infections in Alaskan
Eskimos
IgG seropositivitya Number of patients %
CMV
no 30 5.2
past 8 1.4
new 61 10.5
persistent 483 82.9
HSV1
no 50 8.7
past 5 0.9
new 34 5.9
persistent 484 84.5
HSV2
no 342 59.9
past 9 1.6
new 70 12.3
persistent 150 26.3
Helicobacter pylori
no 71 12.3
past 45 7.8
new 72 12.4
persistent 391 67.5
Chlamydia pneumoniae
no 255 43.6
past 82 14.0
new 78 13.3
persistent 170 29.1
ano: archived sample negative, current sample negative; past: archived sample
positive, current sample negative; new: archived sample negative, current sample
positive; persistent: archived sample positive, current sample positive.
CMV, cytomegalovirus; HSV, herpes simplex virus.
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Fig. 1. Distribution frequency of
individuals showing seropositive
reactions to infectious agents among
610 Alaskan Eskimos.
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demonstrated associations between H. pylori
infection and iron deﬁciency anaemia [20]. The
present study conﬁrmed the previous ﬁnding of
the high prevalence of H. pylori antibodies among
Alaskan Eskimos, and also revealed important
information concerning antibody persistence.
Although the present study did not investigate
the clinical signiﬁcance of these antibodies, the
ﬁndings described in this study should provide
important background information for other
investigators studying infection-related diseases
among Alaskan Eskimos. Compared with western
populations, seropositivity rates to CMV (94%)
and H. pylori (80%) among Eskimos were high,
while the seropositivity to C. pneumoniae (43%)
was relatively low [21]. Low socioeconomic status
is a common feature of populations with a high
prevalence of infection, and this factor probably
plays an important role in the study population.
The Norton Sound region is home to c. 7700
indigenous Alaskan Eskimos, with the 15 small
isolated villages each comprising 38–760 perma-
nent indigenous residents. Interestingly, the anti-
body prevalence for C. pneumoniae, the only
respiratory pathogen studied, was lower in this
isolated population than in industrialised western
countries, suggesting that the spread of this
infection is more dependent on population
density than socioeconomic conditions. Similar
ﬁndings have been reported previously from the
remote Solomon Islands [22]. In addition to
socioeconomic status, other factors responsible
for the observed high seropositivity rates in this
population may include educational levels, poor
sanitary conditions and overcrowded dwellings
(i.e., with close personal contact resulting in
increased risk of person-to-person transmission
of infection).
One of the limitations of the present study was
that additional diagnostic tests for infection, such
as a urea breath test, stool antigen test or pathogen
culture, were not performed. Thus, the serological
results were not compared with tests that reliably
diagnose an active infection. Although commercial
serological assays are used commonly in popula-
tion studies, these assays can give false-positive
results in some populations or individuals with
different ethnic backgrounds, as documented for
H. pylori infection [23]. In addition, studies have
indicated that the presence of IgA is a bettermarker
than IgG for chronicC. pneumoniae infection, as IgG
antibodies often reﬂect previous exposure rather
than ongoing chronic infection [24,25].However, in
the present study, assays for both IgA and IgM
gave low seroprevalence rates (6% for IgA and
0.3% for IgM) for C. pneumoniae. Finally, the
present study population was relatively
small, >80% were smokers, and the cohort did
not include children aged <18 years.
In summary, the study revealed that Alaskan
Eskimos living in the Norton Sound region have a
high prevalence and lifelong persistence of mul-
tiple viral and bacterial antibodies against organ-
isms that have been implicated as playing a
contributing causal role in the development of
atherosclerosis [5–15]. These results provide
important background information for studying
infection-related diseases, including CVD, in
Alaskan Eskimos, and raise the question as to
why such high prevalence and persistence rates of
antibodies to multiple pathogens exist in this
population.
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Table 3. Current prevalence (%) of antibodies according
to age group
IgG Antibody
Age (years)
18–24 25–34 35–44 45–54 55–64 65–74 75+
CMV 94.0 86.2 94.3 94.0 98.4 97.3 100.0
HSV1 90.4 84.4 93.6 93.8 88.7 86.5 93.7
HSV2 15.8 23.8 46.4 55.7 40.3 32.4 62.5
Helicobacter pylori 72.3 81.6 84.8 76.5 87.1 78.4 62.5
Chlamydia pneumoniae 26.7 23.9 33.7 52.9 59.7 81.6 64.7
CMV, cytomegalovirus; HSV, herpes simplex virus.
aAnti-C. pneumoniae IgG titres >1:32 were considered seropositive.
Table 4. Current prevalence of serological markers
according to gender
Seropositivity Females Males
Anti-CMV IgG, % (mean ± SD) 96.9 (3.2 ± 1.0) 89.2 (2.7 ± 1.2)a
Anti-HSV1 IgG, % (mean ± SD) 91.9 (5.5 ± 2.3) 88.6 (5.4 ± 2.6)
Anti-HSV2 IgG, % (mean ± SD) 44.6 (2.2 ± 3.5) 30.9 (1.7 ± 2.8)a
Anti-Helicobacter pylori IgG,
% (mean ± SD)
76.5 (1.6 ± 0.6) 84.4 (1.8 ± 0.6)a
Anti-Chlamydia pneumoniae IgG,
% (mean ± SD)b
38.4 (43.4 ± 85.6) 47.2 (60.6 ± 183.4)a
CMV, cytomegalovirus; HSV, herpes simplex virus.
Data are expressed as a percentage antibody seropositivity and mean level.
ap < 0.05 by v2 test for categorical variables.
bAnti-C. pneumoniae IgG titres >1:32 were considered seropositive.
Zhu et al. Viral and bacterial infections in Eskimos 121
 2006 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 12, 118–122
REFERENCES
1. Maynard JE, Hammes LN, Kester FE. Mortality due to
heart disease among Alaskan Natives 1955–65. Public
Health Reports 1967; 82: 714–720.
2. Newman WP, Middaugh JP, Propst MT, Rogers DR.
Atherosclerosis in Alaska Natives and non-natives. Lancet
1993; 341: 1056–1057.
3. Davidson M, Bulkow LR, Gellin BG. Cardiac mortality in
Alaska’s indigenous and non-native residents. Int J Epi-
demiol 1993; 22: 62–71.
4. Middaugh JP. Cardiovascular deaths among Alaskan
Natives 1980–86. Am J Public Health 1990; 80: 282–285.
5. Epstein SE, Zhou YF, Zhu J. Infection and atherosclerosis:
emerging mechanistic paradigms. Circulation 1999; 100:
e20–e28.
6. Adam E, Probtsﬁeld JL, Burek J et al. High levels of cyto-
megalovirus antibody in patients requiring vascular sur-
gery for atherosclerosis. Lancet 1987; ii: 291–293.
7. Grattan MT, Moreno-Cabral CE, Starnes VA, Oyer PE,
Stinson EB, Shumway NE. Cytomegalovirus infection is
associated with cardiac allograft rejection and athero-
sclerosis. JAMA 1989; 261: 3561–3566.
8. Zhou YF, Leon MB, Waclawiw MA et al. Association
between prior cytomegalovirus infection and the risk of
restenosis after coronary atherectomy. N Engl J Med 1996;
335: 624–630.
9. Nieto FJ, Adam E, Sorlie P et al. Cohort study of
cytomegalovirus infection as a risk factor for carotid inti-
mal-medial thickening, a measure of subclinical athero-
sclerosis. Circulation 1996; 94: 922–927.
10. Saikku P, Leinonen M, Mattila K et al. Serological evidence
of an association of a novel chlamydia, TWAR, with
chronic coronary heart disease and acute myocardial
infarction. Lancet 1988; ii: 983–986.
11. Thom DM, Grayston JT, Siscovitch DS, Wang SP, Weiss
NS, Daling JR. Association of prior infection with Chla-
mydia pneumoniae and angiographically demonstrated
coronary artery disease. JAMA 1992; 268: 68–72.
12. Saikku P, Leinonen M, Tenkanen L et al. Chronic Chla-
mydia pneumoniae infection as a risk factor for coronary
heart disease in the Helsinki heart study. Ann Intern Med
1992; 16: 273–278.
13. Mendall MA, Goggin PM, Molineaux N et al. Relation of
Helicobacter pylori infection and coronary heart disease.
Br Heart J 1994; 71: 437–439.
14. Scragg RKR, Fraser A, Metcalf PA. Helicobacter pylori
seropositivity and cardiovascular risk factors in a multi-
cultural workforce. J Epidemiol Commun Health 1996; 50:
578–579.
15. Pasceri V, Cammarota G, Patti G et al. Association of
virulent Helicobacter pylori strains with ischemic heart
disease. Cirulation 1998; 97: 1675–1679.
16. Wang S. The microimmunoﬂuorescence test for Chlamydia
pneumoniae infection: technique and interpretation. J Infect
Dis 2000; 181 (suppl. 3): 421–425.
17. McKeown I, Orr P, Macdonald S et al. Helicobacter pylori in
the Canadian arctic: seroprevalence and detection in
community water samples. Am J Gastroenterol 1999; 94:
1823–1829.
18. Bernstein CN, McKeown I, Embil JM et al. Seroprevalence
of Helicobacter pylori, incidence of gastric cancer, and
peptic ulcer-associated hospitalizations in a Canadian
Indian population. Dig Dis Sci 1999; 44: 668–674.
19. Parkinson AJ, Gold BD, Bulkow L et al.High prevalence of
Helicobacter pylori in the Alaska native population and
association with low serum ferritin levels in young adults.
Clin Diagn Laboratory Immunol 2000; 7: 885–888.
20. Yip R, Limburg PJ, Ahlquist DA et al. Pervasive occult
gastrointestinal bleeding in an Alaska native population
with prevalent iron deﬁciency: role of Helicobacter pylori
gastritis. JAMA 1997; 277: 1135–1139.
21. Danesh J, Appleby P. Persistent infection and vascular
disease: a systematic review. Exp Opin Invest Drugs 1998; 7:
691–713.
22. Wang SP, Grayston JT. Population prevalence antibody
to Chlamydia pneumoniae, strain TWAR. In: Bowie WR,
Stamm WE, Ward ME et al, eds. Chlamydial infections.
Cambridge: Cambridge University Press 1990, 402–405.
23. Khanna B, Cutler A, Israel NR et al. Use caution with
serologic testing for Helicobacter pylori infection in children.
J Infect Dis 1998; 178: 460–465.
24. Mayr M, Kiechl S, Willeit J, Wick G, Xu Q. Infection,
immunity, and atherosclerosis: associations of antibodies
to Chlamydia pneumoniae, Helicobacter pylori, and
Cytomegalovirus with immune reactions to heat-shock
protein 60 and carotid or femoral atherosclerosis. Circula-
tion 2000; 102: 833–839.
25. Huittinen T, Leinonen M, Tenkanen L et al. Autoimmunity
to human heat shock protein 60, Chlamydia pneumoniae
infection, and inﬂammation in predicting coronary risk.
Arterioscler Thromb Vasc Biol 2002; 22: 431–437.
122 Clinical Microbiology and Infection, Volume 12 Number 2, February 2006
 2006 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 12, 118–122
